Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00198172 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors
A Phase 2 study, sponsored by Indiana University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT00198172 is a Phase 2 study that was terminated before completion, run by Indiana University. The registered enrollment target is 37 participants.
The verdict
NCT00198172, a Phase 2 study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
This study proposes to evaluate the combination of cisplatin plus epirubicin in patients with refractory germ cell tumor not amendable to cure with surgery or standard platinum salvage chemotherapy. This regimen will be used in eligible patients after progression on ECOG Study E39897.
Interventions
- DRUG Cisplatin plus Epirubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2000-10 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00198172
The ClinicalTrials.gov registry entry for NCT00198172 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cisplatin plus Epirubicin is the first listed.
NCT00198172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00198172 about?
NCT00198172 is a clinical study titled "Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors". This study proposes to evaluate the combination of cisplatin plus epirubicin in patients with refractory germ cell tumor not amendable to cure with surgery or standard platinum salvage chemotherapy. This regimen will be used in eligible patients after progression on ECOG Study E39897.
What is the current status of trial NCT00198172?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2000-10. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00198172?
The interventions under investigation include: Cisplatin plus Epirubicin (DRUG).
Who is sponsoring clinical trial NCT00198172?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.